Soheil Meshinchi

Hematology | Oncology

1959 NE Pacific St
Seattle, WA 98195

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 239 publications

AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group.

AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 24, 2026

DNA Methylation of Pharmacologic and Leukemia-Related Genes Predicts Clinical Outcomes in Pediatric Acute Myeloid Leukemia.

DNA Methylation of Pharmacologic and Leukemia-Related Genes Predicts Clinical Outcomes in Pediatric Acute Myeloid Leukemia.

Journal: Cancers

Published: June 23, 2026

FLT3 (CD135) expression in pediatric AML is associated with distinct features and worse outcomes with sorafenib therapy.

FLT3 (CD135) expression in pediatric AML is associated with distinct features and worse outcomes with sorafenib therapy.

Journal: Blood neoplasia

Published: February 26, 2026

HS6ST1 regulates acute myeloid leukemia chemotherapy resistance via TGF-β1 signaling.

HS6ST1 regulates acute myeloid leukemia chemotherapy resistance via TGF-β1 signaling.

Journal: Research square

Published: February 23, 2026

The effect of cohesin mutations on HLA-class II expression in the myeloid leukemia of Down syndrome.

The effect of cohesin mutations on HLA-class II expression in the myeloid leukemia of Down syndrome.

Journal: Leukemia

Published: February 17, 2026

Fully human anti-FOLR1 T-cell engager demonstrates potent activity in CBFA2T3::GLIS2 acute megakaryoblastic leukemia.

Fully human anti-FOLR1 T-cell engager demonstrates potent activity in CBFA2T3::GLIS2 acute megakaryoblastic leukemia.

Journal: Blood neoplasia

Published: January 02, 2026

Clinical implications of RAS mutations in AML: Prognostic significance is based upon involved gene and mutation complexity.

Clinical implications of RAS mutations in AML: Prognostic significance is based upon involved gene and mutation complexity.

Journal: Blood advances

Published: December 08, 2025

Clinical implications of RAS mutations in AML: prognostic significance is based upon the involved gene and mutation complexity.

Clinical implications of RAS mutations in AML: prognostic significance is based upon the involved gene and mutation complexity.

Journal: Blood advances

Published: December 08, 2025

Using genomics to refine pediatric AML risk stratification.

Using genomics to refine pediatric AML risk stratification.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Acute Myeloid Leukemia Relapse after Bromodomain Inhibitor Treatment or Chemotherapy is Characterized by Myc-Ras Transcriptional Remodeling.

Acute Myeloid Leukemia Relapse after Bromodomain Inhibitor Treatment or Chemotherapy is Characterized by Myc-Ras Transcriptional Remodeling.

Journal: bioRxiv : the preprint server for biology

Published: November 26, 2025

Prognostic impact of age and MDS-associated mutations in NPM1 -mutated AML.

Prognostic impact of age and MDS-associated mutations in NPM1 -mutated AML.

Journal: medRxiv : the preprint server for health sciences

Published: November 24, 2025

Prognostic impact of age and MDS-associated mutations in NPM1-mutated AML.

Prognostic impact of age and MDS-associated mutations in NPM1-mutated AML.

Journal: Blood neoplasia

Published: November 21, 2025

Showing 1-12 of 239

Last Updated: 09/26/2026